Galenos. Diagnostics

Main article: Laboratory information systems (PIM, LIS)

"Galenos. Diagnostics" — the module developed by the St. Petersburg IT company "TechLAB" based on the complex Galenos platform is intended for process automation of the direction on researches, routings of the studied materials, data collection, quality control and optimization of the conducted laboratory researches.

The information system also allows to carry out monitoring of accomplishment of testings, to analyze their quantity and quality, to reveal errors in the received materials. As a result process of testing becomes completely transparent. A system is available to simultaneous use by a large number of doctors and medical institutions: in this case access rights to data on patients are just differentiated.

2020: Increase in a possibility of carrying out researches for patients with a breast cancer

On November 30, 2020 IT- the company "TechLAB" reported that it completed participation in the program of support of diagnostics of the HER2 status at patients breast cancer.

"Galenos. Diagnostics" raised a possibility of carrying out researches for patients with a breast cancer. Photo: remedium.ru.

According to the Ministry of Health, the breast cancer takes the second place among oncological diseases: Russia reveals every year 60-70 thousand cases. Increase in survival and decline in mortality of the population from a breast cancer contacts not only large-scale implementation of mammographic screening, but also adequate use of system types of therapy. The pathogenetic variety of RMZh proved using the molecular and genetic analysis and an immunohistochemical research allows to individualize purpose of the most effective types of treatment. In this regard availability and quality improvement of diagnostic testings are extremely important. Both false positive, and false-negative results of diagnostics lead to the non-optimal choice of therapy, decrease in indicators of survival of patients and irrational expenditure of budgetary funds.

At the end of 2016 the biotechnology company BIOCAD started the program of support of diagnostics of the HER2 status at patients with cancer of a mammary gland of HELIOS within which patients in medical institutions – participants of the program had a possibility of receiving an additional cytogenetic research by FISH method. According to the existing international and domestic clinical recommendations about cancer therapy of a mammary gland, these researches are shown to the patients who received a doubtful analysis result of HER2+ of the status when carrying out an immunohistochemical research. In total 67 oncological organizations from 45 regions of Russia took part in the program.

For control, optimization and collection of data on quality of the conducted laboratory researches within the program in organizations the accounting system and processings of results of the diagnostic services rendered to patients – the module "was used by Galenos. Diagnostics", Galenos developed by TechLAB company based on the software.

Module "Galenos. Diagnostics" automated all process of the organization of the program. The staff of participating organizations created in the system of the direction on researches, entered result, could direct the patient's material to additional researches and select organization for their carrying out. The solution completely automated a call of courier service in case of need, allowed to control delivery and receiving material. Using a system TechLAB all received results of the conducted researches of the HER2 status of patients with RMZh gathered that is important for determination of tactics of treatment and purpose of expensive targetny medicines.

Module "Galenos. Diagnostics" it was in addition used for financial management, including control of accomplishment of conditions of agreements with participants and delivery of necessary supplies. Implementation of the module "Galenos. Diagnostics" helped administration of participating organizations to control process of providing diagnostic services and promoted optimization of quality of the conducted researches.

For 3.5 years of program implementation of HELIOS in the module "Galenos. Diagnostics" results of the HER2 status for more than 120 thousand patients were registered.

To more than 8.5 thousand patients according to modern standards within the program cytogenetic researches on a free basis in the leading laboratories of the country were conducted.

Specialists of organizations participated in more than 20 national and regional educational events for the purpose of optimization of quality of the conducted diagnostic testings.

Also in 2018-2019 within HELIOS "The quality test program of laboratory diagnostics" based on the Russian medical academy of life-long professional education (RMAPO) was implemented. One of its tasks is external quality evaluation of laboratory researches. Use of a resource of the module "Galenos. Diagnostics" allowed to automate process and to carry out three rounds of the Program in which 45 laboratories of the Russian Federation took part.

According to the analysis of the received results of researches, for years of project implementation the share of the patients with a breast cancer having the positive status HER2 made 17% that corresponds to universal data. From 2016 to 2020 security with targetny medicines in Russia grew more than by 2.5 times. Use of targetny medicines in medicinal therapy of patients with a HER2 positive breast cancer optimizes results of treatment.

We are glad that took part in such important project. It was our first experience of creation of the accounting and logistic platform for the project on diagnostics sponsored by the large pharmaceutical company. Even if in regional laboratory there are no technical capabilities for accomplishment of a research, using our system material can be sent to other laboratory or in general to other region, including to the largest centers of the country and to receive results at once upon readiness in electronic form. Alexander Shapovalov, the director of TechLAB IT company told

2017: Help in diagnosis of cancer in 42 regions of Russia

According to data of TechLAB company, in 2017 a system "Galenos. Diagnostics" helped to diagnose a breast cancer in 42 regions of Russia. So, for all 2017 in the solution "Galenos. Diagnostics" 32,651 researches among which in 4,767 cases the "HER2 positive" molecular and biological subtype defining high efficiency of use of targetny therapy was confirmed were recorded. 11,232 more cases were defined as "lyuminalny And yes In" at which use of hormonal medicinal therapy is highly effective. Thus, using IT solution the effectiveness of treatment and chances of patients of long remission increases, reported TAdviser on August 30, 2018 in TechLAB.

Russia annually fixes about 60 thousand new cases which developed a breast cancer told in the company. According to official data, it is a basic reason of oncological death rate among women — more than 23 thousand people die every year of a disease. Emergence of new methods of treatment, in particular biological substances, influences decline in mortality from this kind of cancer. However doctors and experts recognize: to increase survival of patients with a breast cancer, it is necessary to improve seriously screening and early detection of tumors.

As emphasized in TechLAB, determination of the HER2 status — one of important diagnostic procedures for obtaining information on a tumor, on an equal basis with delimitation of a tumor and the receptor statuses of estrogen and progesterone. The positive HER2 status, i.e. existence of this receptor, or growth factor, on a surface of a cancer tumor, forces the cages affected with a disease to be multiplied promptly.

Patients with the HER2 positive status of a breast cancer should receive the additional therapy which is slowing down growth of a tumor since early stages of a disease. In other words, the choice of the scheme of treatment of the patient depends on the accuracy of diagnostics of the HER2 status. Therefore for the patients with cancer of a mammary gland who received a doubtful analysis result when carrying out an immunohistochemical research in 42 regions of Russia the program of support of molecular diagnostics of the HER2 status is implemented — explained in the company. — Within this program for increase in accuracy, quality of the laboratory researches defining the HER2 status, and volumes of the processed data on patients the module "is used by Galenos. Diagnostics".

According to representatives TechLAB, IT solution for diagnostics of the HER2 status helps to collect statistical information on results of the conducted researches in medical institutions. At the same time to use a system "Galenos. Diagnostics" can at the same time large number of doctors and medical institutions — in this case access rights to data on patients are just differentiated.

First, it helps to maintain quality and to compare results of researches between organizations. As a result performing exact and timely diagnostics of the HER2 status according to modern standards becomes available all patient with cancer of a mammary gland. Secondly, a system helps to identify the women needing vital anti-HER2-therapy and to distribute them on medical institutions depending on existence in clinics of the corresponding medicines. And, besides, processing of the depersonalized statistical information on patients gives the chance to collect up-to-date data about prevalence of a HER2 positive breast cancer in Russia and to define what medicines and in what quantities are necessary in medical institutions — concluded in TechLAB.